A Dermatologist Guide to Immunogenicity

Overview

Journal Int J Womens Dermatol

Publisher Wolters Kluwer

Date 2017 May 12

PMID 28492015

Citations 1

Authors

Collin M Blattner

Soham P Chaudhari

John Young 3rd

Jenny E Murase

Affiliations

Soon will be listed here.

Abstract

Dermatologists should be aware that autoantibody formation may occur after the initiation of biologic therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this, patients may experience loss of clinical efficacy to a particular drug. To combat this phenomenon, low-dose immunomodulators may be used in hopes of preventing autoantibodies. We review the current literature and provide a basic treatment algorithm for patients with moderate to severe psoriasis.

Citing Articles

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis.

Valenzuela F, Flores R Clinics (Sao Paulo). 2021; 76:e3015.

PMID: 34614113 PMC: 8449932. DOI: 10.6061/clinics/2021/e3015.

References

Nast A, Kopp I, Augustin M, Banditt K, Boehncke W, Follmann M . Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges. 2007; 5 Suppl 3:1-119. DOI: 10.1111/j.1610-0387.2007.06172.x. View

Gottlieb A, Langley R, Strober B, Papp K, Klekotka P, Creamer K . A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012; 167(3):649-57. PMC: 3504074. DOI: 10.1111/j.1365-2133.2012.11015.x. View

Menter A, Feldman S, Weinstein G, Papp K, Evans R, Guzzo C . A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2006; 56(1):31.e1-15. DOI: 10.1016/j.jaad.2006.07.017. View

Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4. View

Antoniou C, Dessinioti C, Vergou T, Stratigos A, Avgerinou G, Kostaki M . Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis. J Eur Acad Dermatol Venereol. 2010; 24(12):1413-20. DOI: 10.1111/j.1468-3083.2010.03661.x. View

Scott D, De Groot A . Can we prevent immunogenicity of human protein drugs?. Ann Rheum Dis. 2009; 69 Suppl 1:i72-76. DOI: 10.1136/ard.2009.117564. View

Rutgeerts P, Van Assche G, Vermeire S . Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006; 23(4):451-63. DOI: 10.1111/j.1365-2036.2006.02786.x. View

Bartelds G, Wijbrandts C, Nurmohamed M, Stapel S, Lems W, Aarden L . Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007; 66(7):921-6. PMC: 1955110. DOI: 10.1136/ard.2006.065615. View

DAngelo S, Cutro M, Lubrano E, Leccese P, Mennillo G, Ferrara N . Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis. Ann Rheum Dis. 2009; 69(5):934-5. DOI: 10.1136/ard.2009.119446. View

10.

Saraceno R, Saggini A, Pietroleonardo L, Chimenti S . Infliximab in the treatment of plaque type psoriasis. Clin Cosmet Investig Dermatol. 2011; 2:27-37. PMC: 3047936. DOI: 10.2147/ccid.s3413. View

11.

Dalaker M, Bonesronning J . Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J Eur Acad Dermatol Venereol. 2009; 23(3):277-82. DOI: 10.1111/j.1468-3083.2008.03039.x. View

12.

Lee E, Shin M, Kim N . A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis. Ann Dermatol. 2010; 22(2):138-42. PMC: 2883414. DOI: 10.5021/ad.2010.22.2.138. View

13.

Cheifetz A, Mayer L . Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005; 72(4):250-6. View

14.

Baert F, De Vos M, Louis E, Vermeire S . Immunogenicity of infliximab: how to handle the problem?. Acta Gastroenterol Belg. 2007; 70(2):163-70. View

15.

Aksu K, Cagirgan S, Ozsan N, Keser G, Sahin F . Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int. 2009; 31(12):1645-7. DOI: 10.1007/s00296-009-1265-0. View

16.

Carrascosa J, van Doorn M, Lahfa M, Nestle F, Jullien D, Prinz J . Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies. J Eur Acad Dermatol Venereol. 2014; 28(11):1424-30. DOI: 10.1111/jdv.12549. View

17.

Boffa M . Methotrexate for psoriasis: current European practice. A postal survey. J Eur Acad Dermatol Venereol. 2005; 19(2):196-202. DOI: 10.1111/j.1468-3083.2004.01140.x. View

18.

Mikuls T, ODell J . The changing face of rheumatoid arthritis therapy: results of serial surveys. Arthritis Rheum. 2000; 43(2):464-5. DOI: 10.1002/1529-0131(200002)43:2<464::AID-ANR30>3.0.CO;2-U. View

19.

Eklund K, Peltomaa R, Leirisalo-Repo M . Occurrence of pulmonary thromboembolism during infliximab therapy. Clin Exp Rheumatol. 2003; 21(5):679. View

20.

Cassinotti A, Travis S . Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009; 15(8):1264-75. DOI: 10.1002/ibd.20899. View